View in EDS

P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia.

Saved in:
Bibliographic Details
Title: P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia.
Authors: Lin KH; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA., Rutter JC; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA., Xie A; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA., Killarney ST; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA., Vaganay C; Université de Paris, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, Paris, France., Benaksas C; Université de Paris, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, Paris, France., Ling F; Université de Paris, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, Paris, France., Sodaro G; Université de Paris, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, Paris, France., Meslin PA; Université de Paris, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, Paris, France., Bassil CF; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA., Fenouille N; Université de Paris, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, Paris, France., Hoj J; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA., Washart R; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA., Ang HX; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA., Cerda-Smith C; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA., Chaintreuil P; Université Côte d'Azur, Nice, France., Jacquel A; Université Côte d'Azur, Nice, France., Auberger P; Université Côte d'Azur, Nice, France., Forget A; Université de Paris, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, Paris, France., Itzykson R; Université de Paris, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, Paris, France., Lu M; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA., Lin J; Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA., Pierobon M; Center for Applied Proteomics and Molecular Medicine, School of Systems Biology, George Mason University, Manassas, VA, USA., Sheng Z; Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA., Li X; Department of Biomedical Engineering, Duke University, Durham, NC, USA., Chilkoti A; Department of Biomedical Engineering, Duke University, Durham, NC, USA., Owzar K; Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA., Rizzieri DA; Department of Medicine, Duke University Medical Center, Durham, NC, USA., Pardee TS; Department of Internal Medicine, Section on Hematology and Oncology, Wake Forest Baptist Health, Winston-Salem, NC, USA., Benajiba L; Université de Paris, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, Paris, France., Petricoin E; Center for Applied Proteomics and Molecular Medicine, School of Systems Biology, George Mason University, Manassas, VA, USA., Puissant A; Université de Paris, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, Paris, France. alexandre.puissant@inserm.fr., Wood KC; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA. kris.wood@duke.edu.
Source: Nature cancer [Nat Cancer] 2022 Jul; Vol. 3 (7), pp. 837-851. Date of Electronic Publication: 2022 Jun 06.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101761119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2662-1347 (Electronic) Linking ISSN: 26621347 NLM ISO Abbreviation: Nat Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35668193
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Lin+KH%22">Lin KH</searchLink>; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA.<br /><searchLink fieldCode="AU" term="%22Rutter+JC%22">Rutter JC</searchLink>; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA.<br /><searchLink fieldCode="AU" term="%22Xie+A%22">Xie A</searchLink>; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA.<br /><searchLink fieldCode="AU" term="%22Killarney+ST%22">Killarney ST</searchLink>; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA.<br /><searchLink fieldCode="AU" term="%22Vaganay+C%22">Vaganay C</searchLink>; Université de Paris, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, Paris, France.<br /><searchLink fieldCode="AU" term="%22Benaksas+C%22">Benaksas C</searchLink>; Université de Paris, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, Paris, France.<br /><searchLink fieldCode="AU" term="%22Ling+F%22">Ling F</searchLink>; Université de Paris, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, Paris, France.<br /><searchLink fieldCode="AU" term="%22Sodaro+G%22">Sodaro G</searchLink>; Université de Paris, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, Paris, France.<br /><searchLink fieldCode="AU" term="%22Meslin+PA%22">Meslin PA</searchLink>; Université de Paris, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, Paris, France.<br /><searchLink fieldCode="AU" term="%22Bassil+CF%22">Bassil CF</searchLink>; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA.<br /><searchLink fieldCode="AU" term="%22Fenouille+N%22">Fenouille N</searchLink>; Université de Paris, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, Paris, France.<br /><searchLink fieldCode="AU" term="%22Hoj+J%22">Hoj J</searchLink>; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA.<br /><searchLink fieldCode="AU" term="%22Washart+R%22">Washart R</searchLink>; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA.<br /><searchLink fieldCode="AU" term="%22Ang+HX%22">Ang HX</searchLink>; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA.<br /><searchLink fieldCode="AU" term="%22Cerda-Smith+C%22">Cerda-Smith C</searchLink>; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA.<br /><searchLink fieldCode="AU" term="%22Chaintreuil+P%22">Chaintreuil P</searchLink>; Université Côte d'Azur, Nice, France.<br /><searchLink fieldCode="AU" term="%22Jacquel+A%22">Jacquel A</searchLink>; Université Côte d'Azur, Nice, France.<br /><searchLink fieldCode="AU" term="%22Auberger+P%22">Auberger P</searchLink>; Université Côte d'Azur, Nice, France.<br /><searchLink fieldCode="AU" term="%22Forget+A%22">Forget A</searchLink>; Université de Paris, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, Paris, France.<br /><searchLink fieldCode="AU" term="%22Itzykson+R%22">Itzykson R</searchLink>; Université de Paris, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, Paris, France.<br /><searchLink fieldCode="AU" term="%22Lu+M%22">Lu M</searchLink>; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA.<br /><searchLink fieldCode="AU" term="%22Lin+J%22">Lin J</searchLink>; Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA.<br /><searchLink fieldCode="AU" term="%22Pierobon+M%22">Pierobon M</searchLink>; Center for Applied Proteomics and Molecular Medicine, School of Systems Biology, George Mason University, Manassas, VA, USA.<br /><searchLink fieldCode="AU" term="%22Sheng+Z%22">Sheng Z</searchLink>; Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA.<br /><searchLink fieldCode="AU" term="%22Li+X%22">Li X</searchLink>; Department of Biomedical Engineering, Duke University, Durham, NC, USA.<br /><searchLink fieldCode="AU" term="%22Chilkoti+A%22">Chilkoti A</searchLink>; Department of Biomedical Engineering, Duke University, Durham, NC, USA.<br /><searchLink fieldCode="AU" term="%22Owzar+K%22">Owzar K</searchLink>; Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA.<br /><searchLink fieldCode="AU" term="%22Rizzieri+DA%22">Rizzieri DA</searchLink>; Department of Medicine, Duke University Medical Center, Durham, NC, USA.<br /><searchLink fieldCode="AU" term="%22Pardee+TS%22">Pardee TS</searchLink>; Department of Internal Medicine, Section on Hematology and Oncology, Wake Forest Baptist Health, Winston-Salem, NC, USA.<br /><searchLink fieldCode="AU" term="%22Benajiba+L%22">Benajiba L</searchLink>; Université de Paris, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, Paris, France.<br /><searchLink fieldCode="AU" term="%22Petricoin+E%22">Petricoin E</searchLink>; Center for Applied Proteomics and Molecular Medicine, School of Systems Biology, George Mason University, Manassas, VA, USA.<br /><searchLink fieldCode="AU" term="%22Puissant+A%22">Puissant A</searchLink>; Université de Paris, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, Paris, France. alexandre.puissant@inserm.fr.<br /><searchLink fieldCode="AU" term="%22Wood+KC%22">Wood KC</searchLink>; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA. kris.wood@duke.edu.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101761119%22">Nature cancer</searchLink> [Nat Cancer] 2022 Jul; Vol. 3 (7), pp. 837-851. <i>Date of Electronic Publication: </i>2022 Jun 06.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Group%22">Nature Publishing Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101761119 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2662-1347 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2226621347%22">26621347 </searchLink><i>NLM ISO Abbreviation: </i>Nat Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35668193
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s43018-022-00394-x
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 837
    Titles:
      – TitleFull: P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Lin KH
      – PersonEntity:
          Name:
            NameFull: Rutter JC
      – PersonEntity:
          Name:
            NameFull: Xie A
      – PersonEntity:
          Name:
            NameFull: Killarney ST
      – PersonEntity:
          Name:
            NameFull: Vaganay C
      – PersonEntity:
          Name:
            NameFull: Benaksas C
      – PersonEntity:
          Name:
            NameFull: Ling F
      – PersonEntity:
          Name:
            NameFull: Sodaro G
      – PersonEntity:
          Name:
            NameFull: Meslin PA
      – PersonEntity:
          Name:
            NameFull: Bassil CF
      – PersonEntity:
          Name:
            NameFull: Fenouille N
      – PersonEntity:
          Name:
            NameFull: Hoj J
      – PersonEntity:
          Name:
            NameFull: Washart R
      – PersonEntity:
          Name:
            NameFull: Ang HX
      – PersonEntity:
          Name:
            NameFull: Cerda-Smith C
      – PersonEntity:
          Name:
            NameFull: Chaintreuil P
      – PersonEntity:
          Name:
            NameFull: Jacquel A
      – PersonEntity:
          Name:
            NameFull: Auberger P
      – PersonEntity:
          Name:
            NameFull: Forget A
      – PersonEntity:
          Name:
            NameFull: Itzykson R
      – PersonEntity:
          Name:
            NameFull: Lu M
      – PersonEntity:
          Name:
            NameFull: Lin J
      – PersonEntity:
          Name:
            NameFull: Pierobon M
      – PersonEntity:
          Name:
            NameFull: Sheng Z
      – PersonEntity:
          Name:
            NameFull: Li X
      – PersonEntity:
          Name:
            NameFull: Chilkoti A
      – PersonEntity:
          Name:
            NameFull: Owzar K
      – PersonEntity:
          Name:
            NameFull: Rizzieri DA
      – PersonEntity:
          Name:
            NameFull: Pardee TS
      – PersonEntity:
          Name:
            NameFull: Benajiba L
      – PersonEntity:
          Name:
            NameFull: Petricoin E
      – PersonEntity:
          Name:
            NameFull: Puissant A
      – PersonEntity:
          Name:
            NameFull: Wood KC
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 07
              Text: 2022 Jul
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 2662-1347
          Numbering:
            – Type: volume
              Value: 3
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: Nature cancer
              Type: main
ResultId 1